axa wealths platform leads
Axa UK posted what it has termed a “strong turn-around” of UK operations today with sales onto Axa Wealth’s Elevate Platform up 75% and an increase in FUM for its multi-manager business, Architas.
Axa UK posted what it has termed a “strong turn-around” of UK operations today with sales onto Axa Wealth’s Elevate Platform up 75% and an increase in FUM for its multi-manager business, Architas.
Chris Iggo gives his motivations to buy long duration and suggests ‘equity-lite’ for those who are more positive about the global economy.
Todays big news sees Theo Zemek bring down the curtain on her frontline fund management career, presumably permanently, as she focuses on her senior management role as part of Axa IMs board. But what exactly does this mean for the firms fixed income capabilities, and does Nick Hayes have the right credentials as her replacement?
Nick Hayes has taken over from Theodora Zemek as the lead manager of the Axa Sterling Corporate Bond Fund, as he continues to make his mark on the Axa IM fixed income team.
Axa Investment Managers has rejigged its joint venture in India, signing a deal to take advantage of Bank of India’s distribution capability.
Axa IM has announced the appointment of Benjamin Rumary as investment sales manager for the Channel Islands, Ireland and South West.
AXA Investment Managers has confirmed it plans to launch a global strategic bond fund for its fixed income manager Nick Hayes in the New Year.
Axa Investment Managers has launched a high conviction global income fund targeting between 1.5 and 2.5 times the yield of the MSCI AC World index.
Chris Iggo looks at the complications over how banks will fund the higher levels of capital regulation is forcing them to hold.
Chris Iggo is downbeat over the UK – any growth is still weak – and the fact it is doing better than continental Europe doesn’t cut the mustard.
Axa Wealth unveils its strategy for investment in its platform and brand with a string of painful marketing clichés.
Axa Wealth’s chief executive argues against the potential for the FSA to delay banning legacy commission.